Trends in biomarker research for cancer detection

Lancet Oncology

Volumn 2, Issue 11, 2001, Pages 698-704

  Srinivas, Pothur R ^a   Kramer, Barnett S ^b   Srivastava, Sudhir ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GENE PRODUCT; ORGANIC COMPOUND; PROTEIN; PROTEOME;

ARTICLE; CANCER CELL; CANCER CENTER; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; CELL FUNCTION; CELL ISOLATION; CELL TRANSFORMATION; CHEEK; COMPLEX FORMATION; CYTOLOGY; EARLY DIAGNOSIS; GENETIC ANALYSIS; GENOME; HUMAN; HUMAN CELL; MEDICAL ASSESSMENT; MEDICAL TECHNOLOGY; METHYLATION; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; MORBIDITY; NON INVASIVE MEASUREMENT; PLASMA; PRECANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

EID: 0035183179     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00560-5     Document Type: Note

References (47)

1. Colorectal risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes
2. Usefulness of genetic susceptibility and biomarkers for evaluation of environmental health risk
3. Cytogenetic markers of susceptibility: Influence of polymorphic carcinogen-metabolizing enzymes
4. Understanding PSA and prostate cancer risk assessment
5. Soluble interleukin-2 receptor levels in hepatocellular cancer: A more sensitive marker than alfa fetoprotein
6. Microsatellite instability in cancer of the proximal colon
7. Mismatch repair and cancer
8. Clues to the pathogenesis of familial colorectal cancer
9. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer
10. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer
11. Mismatch repair defects in cancer
12. Aberrant CpG-island methylation has non-random and tumour-type specific patterns
13. DNA Methylation: Past, present and future directions
14. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal cancer
15. Hypermethylation can selectively silence individual p161NK4a alleles in neoplasia
16. Mutation hotspots and DNA methylation
17. Cancer epigenetics comes of age
18. Aging, methylation and cancer
19. Microsatellite alternations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance
20. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer
21. Epigenetic patterns in the progression of esophageal adenocarcinoma
22. Suppression of intestinal neoplasia by DNA hypomethylation
23. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
24. Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug metabolizing genes, their functional importance and nomenclature issues
25. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays
26. Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers
27. Bead based fiber-optic arrays
28. Expression profiling in cancer using cDNA microarrays
29. Serial analysis of gene expression
30. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
31. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
32. Serial analysis of gene expression: From gene discovery to target identification
33. Gene amplification as a means for determining therapeutic strategies in human cancers
34. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it
35. Proteomics to study genes and genomes
36. Development of a novel proteomics approach for the detection of transitional cell carcinoma of the bladder in urine
37. Cancer proteomics: From identification of novel markers to creation of artifical learning models for tumour classification
38. DNA methylation: An alternate pathway to cancer
39. TP53 gene mutations in plasma DNA of cancer patients
40. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients
41. Microsatellite alterations in serum DNA of head and neck cancer patients
42. Microsatellite alterations in plasma DNA of small cell lung cancer patients
43. Genetic analysis of DNA excreted in urine: A new approach for detecting specific genomic DNA sequences from cells dying in an organism
44. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel
45. Exfoliative cytology of normal buccal mucosa to predict the relative risk of cancer in the upper aerodigestive tract using the MN-assay
46. Potential early markers of carcinogenesis in the mucosa of the head and neck using exfoliative cytology
47. Predicting lung cancer by detecting aberrant promoter methylation in sputum